Tags

Type your tag names separated by a space and hit enter

Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Neuropsychopharmacol Rep. 2020 Jun; 40(2):138-149.NR

Abstract

AIM

It is well accepted that early improvement with antipsychotics predicts subsequent response in patients with schizophrenia. However, no study has examined the contribution of individual symptoms rather than overall symptom severity as the predictors. Thus, we aimed to detect individual symptoms whose improvements could predict subsequent response in patients with schizophrenia during treatment with asenapine and examine whether a prediction model with individual symptoms would be superior to a model using overall symptom severity.

METHODS

This study analyzed a dataset including 532 patients with schizophrenia enrolled in a 6-week double-blind, placebo-controlled, randomized trial of asenapine. Response to asenapine was defined as a ≥30% decrease in Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 6. Stepwise logistic regression analyses were performed to investigate the associations among response and PANSS total/individual item score improvements at week 1 or week 2.

RESULTS

Response was associated with early improvement in the following PANSS items: disturbance of volition, active social avoidance, poor impulse control at week 1; and active social avoidance, poor attention, lack of judgment and insight at week 2. Prediction accuracy was almost compatible between the model with individual symptoms and the model with PANSS total score both at weeks 1 and 2 (Nagelkerke R2 : .51, .42 and .55, .54, respectively).

CONCLUSION

Early improvement in negative symptoms, poor attention and impulse control, and lack of insight, in particular predicted subsequent treatment response in patients with schizophrenia during treatment with asenapine as accurately as prediction based on overall symptom severity.

Authors+Show Affiliations

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Pharmacogenetic Research Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Cerebral Imaging Centre, Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Multimodal Imaging Group, Research Imaging Centre, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32180369

Citation

Ogyu, Kamiyu, et al. "Early Improvements of Individual Symptoms as a Predictor of Treatment Response to Asenapine in Patients With Schizophrenia." Neuropsychopharmacology Reports, vol. 40, no. 2, 2020, pp. 138-149.
Ogyu K, Noda Y, Yoshida K, et al. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. Neuropsychopharmacol Rep. 2020;40(2):138-149.
Ogyu, K., Noda, Y., Yoshida, K., Kurose, S., Masuda, F., Mimura, Y., Nishida, H., Plitman, E., Tarumi, R., Tsugawa, S., Wada, M., Miyazaki, T., Uchida, H., Graff-Guerrero, A., Mimura, M., & Nakajima, S. (2020). Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. Neuropsychopharmacology Reports, 40(2), 138-149. https://doi.org/10.1002/npr2.12103
Ogyu K, et al. Early Improvements of Individual Symptoms as a Predictor of Treatment Response to Asenapine in Patients With Schizophrenia. Neuropsychopharmacol Rep. 2020;40(2):138-149. PubMed PMID: 32180369.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. AU - Ogyu,Kamiyu, AU - Noda,Yoshihiro, AU - Yoshida,Kazunari, AU - Kurose,Shin, AU - Masuda,Fumi, AU - Mimura,Yu, AU - Nishida,Hana, AU - Plitman,Eric, AU - Tarumi,Ryosuke, AU - Tsugawa,Sakiko, AU - Wada,Masataka, AU - Miyazaki,Takahiro, AU - Uchida,Hiroyuki, AU - Graff-Guerrero,Ariel, AU - Mimura,Masaru, AU - Nakajima,Shinichiro, Y1 - 2020/03/16/ PY - 2019/12/03/received PY - 2020/01/02/revised PY - 2020/01/06/accepted PY - 2020/3/18/pubmed PY - 2020/3/18/medline PY - 2020/3/18/entrez KW - antipsychotic KW - asenapine KW - early improvement KW - prediction KW - response KW - schizophrenia SP - 138 EP - 149 JF - Neuropsychopharmacology reports JO - Neuropsychopharmacol Rep VL - 40 IS - 2 N2 - AIM: It is well accepted that early improvement with antipsychotics predicts subsequent response in patients with schizophrenia. However, no study has examined the contribution of individual symptoms rather than overall symptom severity as the predictors. Thus, we aimed to detect individual symptoms whose improvements could predict subsequent response in patients with schizophrenia during treatment with asenapine and examine whether a prediction model with individual symptoms would be superior to a model using overall symptom severity. METHODS: This study analyzed a dataset including 532 patients with schizophrenia enrolled in a 6-week double-blind, placebo-controlled, randomized trial of asenapine. Response to asenapine was defined as a ≥30% decrease in Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 6. Stepwise logistic regression analyses were performed to investigate the associations among response and PANSS total/individual item score improvements at week 1 or week 2. RESULTS: Response was associated with early improvement in the following PANSS items: disturbance of volition, active social avoidance, poor impulse control at week 1; and active social avoidance, poor attention, lack of judgment and insight at week 2. Prediction accuracy was almost compatible between the model with individual symptoms and the model with PANSS total score both at weeks 1 and 2 (Nagelkerke R2 : .51, .42 and .55, .54, respectively). CONCLUSION: Early improvement in negative symptoms, poor attention and impulse control, and lack of insight, in particular predicted subsequent treatment response in patients with schizophrenia during treatment with asenapine as accurately as prediction based on overall symptom severity. SN - 2574-173X UR - https://www.unboundmedicine.com/medline/citation/32180369/Early_improvements_of_individual_symptoms_as_a_predictor_of_treatment_response_to_asenapine_in_patients_with_schizophrenia L2 - https://doi.org/10.1002/npr2.12103 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.